---
title: "Genenta Science S.p.A. (GNTA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GNTA.US.md"
symbol: "GNTA.US"
name: "Genenta Science S.p.A."
industry: "Biotechnology"
datetime: "2026-06-16T10:44:42.239Z"
locales:
  - [en](https://longbridge.com/en/quote/GNTA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GNTA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GNTA.US.md)
---

# Genenta Science S.p.A. (GNTA.US)

## Company Overview

Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.genenta.com](https://www.genenta.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.64 | 395 | - | - | - |
| PB | 1.66 | 164 | 4.69 | 2.46 | 1.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-22T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.80 |
| Highest Target | 6.97 |
| Lowest Target | 6.97 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GNTA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GNTA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GNTA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GNTA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**